9 January 2024
The opioid epidemic in the US is a severe public health crisis, with increasing misuse, addiction, and overdose deaths. Central to tackling opioid dependence are dedicated treatment plans using opioid substitute therapy. However, as the crises evolves into its now fourth wave, different regions are exposed to different concoctions of drugs and so a more personalized approach to evaluating compliance with therapy is required.
Speaking with Dr. JP Canner, Chief Scientific Officer and Laboratory Director at Gravity Diagnostics, we explore how this state-of-the-art CAP-accredited and CLIA-certified laboratory is expanding its drug testing menus to respond to regional drug use patterns seen as part of its clinical toxicology services.